EVFMOTCPharmaceutical PreparationsFiscal year ends December 31

Evofem Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.01−0.00 (-10.00%)

Close on Oct 19, 2026

Community

Notes and questions about Evofem Biosciences from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Evofem Biosciences's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-125 reverse split on Jun 16, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVFM.

Revenue growth4.5% · median 312.6%

Gross margin75.5% · median 88.0%

Operating margin-15.3% · median -105.4%

Net margin-84.7% · median -53.3%

Advertisement
300 × 250